BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. [electronic resource]
Producer: 20080717Description: 2194-201 p. digitalISSN:- 0021-972X
- Animals
- Antineoplastic Agents -- pharmacology
- Benzamides -- pharmacology
- Benzimidazoles -- pharmacology
- Carcinoma -- enzymology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Diphenylamine -- analogs & derivatives
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Mice
- Mice, Nude
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Mutation, Missense
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins B-raf -- genetics
- Substrate Specificity
- Thyroid Neoplasms -- enzymology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.